[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 963111, "exercisedValue": 0, "unexercisedValue": 2049802}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 37, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 595515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 676166, "exercisedValue": 0, "unexercisedValue": 234059}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 59, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.7, "open": 2.68, "dayLow": 2.61, "dayHigh": 2.81, "regularMarketPreviousClose": 2.7, "regularMarketOpen": 2.68, "regularMarketDayLow": 2.61, "regularMarketDayHigh": 2.81, "payoutRatio": 0.0, "forwardPE": -0.79710144, "volume": 63013, "regularMarketVolume": 63013, "averageVolume": 214003, "averageVolume10days": 66100, "averageDailyVolume10Day": 66100, "bid": 2.66, "ask": 2.86, "bidSize": 1, "askSize": 1, "marketCap": 67170952, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 2.27, "twoHundredDayAverage": 5.255325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -61970156, "profitMargins": 0.0, "floatShares": 5979427, "sharesOutstanding": 24363100, "sharesShort": 306194, "sharesShortPriorMonth": 650018, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0126, "heldPercentInsiders": 0.19939, "heldPercentInstitutions": 0.75842005, "shortRatio": 1.2, "shortPercentOfFloat": 0.0315, "impliedSharesOutstanding": 24425800, "bookValue": 6.11, "priceToBook": 0.45008183, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -75132000, "trailingEps": -6.15, "forwardEps": -3.45, "enterpriseToEbitda": 0.784, "52WeekChange": -0.73608446, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 2.75, "targetHighPrice": 19.0, "targetLowPrice": 10.0, "targetMeanPrice": 15.4, "targetMedianPrice": 18.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 142364992, "totalCashPerShare": 5.828, "ebitda": -79073000, "totalDebt": 13224000, "quickRatio": 13.317, "currentRatio": 13.843, "totalRevenue": 0, "debtToEquity": 8.873, "revenuePerShare": 0.0, "returnOnAssets": -0.41573003, "returnOnEquity": -0.86182, "grossProfits": 0, "freeCashflow": -45932376, "operatingCashflow": -69085000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "regularMarketChangePercent": 1.85185, "regularMarketPrice": 2.75, "marketState": "CLOSED", "twoHundredDayAverageChangePercent": -0.47672123, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "postMarketPrice": 2.75, "postMarketChange": 0.0, "regularMarketChange": 0.05, "regularMarketDayRange": "2.61 - 2.81", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 214003, "fiftyTwoWeekLowChange": 1.28, "fiftyTwoWeekLowChangePercent": 0.8707483, "fiftyTwoWeekRange": "1.47 - 17.31", "fiftyTwoWeekHighChange": -14.559999, "fiftyTwoWeekHighChangePercent": -0.8411323, "fiftyTwoWeekChangePercent": -73.608444, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.15, "epsForward": -3.45, "epsCurrentYear": -3.13, "priceEpsCurrentYear": -0.8785942, "fiftyDayAverageChange": 0.48000002, "fiftyDayAverageChangePercent": 0.21145375, "twoHundredDayAverageChange": -2.5053248, "corporateActions": [], "postMarketTime": 1755288603, "regularMarketTime": 1755288002, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": 0.0, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]